Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (5R01AI132178)
Text and Data Mining valid from 2020-01-10
Received: 3 January 2019
Accepted: 7 December 2019
First Online: 10 January 2020
: A.C.S. received a contract from Gilead Sciences to support the in vitro and in vivo efficacy studies reported herein. These authors are employees of Gilead Sciences and hold stock in Gilead Sciences: Alison Hogg, Darius Babusis, Michael O. Clarke, Jamie E. Spahn, Laura Bauer, Scott Sellers, Danielle Porter, Joy Y. Feng, Tomas Cihlar, and Robert Jordan.